A study on 3.7 million individuals at the New York University School of Medicine shows an 18 percent lower risk of peripheral artery disease (PAD) with the consumption of at least three pieces of fruit and vegetables per day when compared with those individuals who are consuming less.
The study shows about 6.3 percent of the population was affected by the peripheral artery disease (PAD) and about 29.2 percent of people are consuming at least three servings of fruit and vegetables.
This study shows the significance of consuming fruit and vegetables in lowering the risk associated with peripheral artery disease (PAD). This study also confirms a dismally low consumption of the fruit and vegetables among citizens.
The study has found that the highest number of older white women are consuming at least three servings of fruit and vegetables and the lowest number of younger black men are consuming the fewer servings of fruit and vegetables.
The author of the study was Dr. Jeffrey Berger, an associate professor of medicine and surgery, the New York University School of Medicine. The co-author of the study was Sean Heffron, the New York University School of Medicine.
The study was published on May 18, 2017, in the American Heart Association journal Arteriosclerosis, Thrombosis and Vascular Biology. Title of the article is "Greater Frequency of Fruit and Vegetable Consumption Is Associated With Lower Prevalence of Peripheral Artery Disease."
Israeli scientists from the Sheba Medical Center and the Ben-Gurion University of the Negev have developed a new and innovative treatment for atherosclerosis and to fight against stroke and heart diseases.
The new treatment option can lower the plaque and inflammation in the arteries, which is transporting the blood rich with the oxygen and nutrients to organs, tissues and cells. The new therapy can prevent the future development of plaque and inflammation.
The plaque formation in the arteries is a risk factor for diseases such as arterial thrombosis, myocardial infarction, ischemia and stroke. The following are the benefits of biomedical nano-polymer therapy.
The patented polymer-based therapy is in the preclinical stage. The experiment on the mice models are positive and there is a remarkable improvement in the health of the arteries. The thickness of the arteries is lowered and there is less inflammation.
The scientists say that the new therapy can help a patient in lowering the health risk associated with the old age such as high blood pressure (hypertension. BP), high cholesterol level and high blood sugar (glucose) level (type 2 diabetes).
Dr. Ora Horovitz, senior vice president of business development at the BGN Technologies, the technology transfer division of the Ben-Gurion University of the Negev, says that they are looking for a pharmaceutical company for the further development and marketing of the new therapy.
The researchers at the University of Adelaide have developed a new type 2 diabetes (T2D) drug that can work effectively in lowering the blood sugar (glucose) level in a patient with a fewer number of insulin injections.
The drug can increase insulin level and change the metabolism of fat and sugar. The original version of the drug (INT131) is currently under clinical trial in the United States. The latest version of the drug was improved even further for the treatment of type 2 diabetes.
The lead researcher of the study was Dr. John B. Bruning, Senior Lecturer, The University of Adelaide, Australia.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.